drugset / Trial / NCT00310596

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

NCT00310596

Phase 1 Completed 71 enrolled Bayer
RandomizedCrossoverTriple-blindDiagnostic

Summary

The purpose of this study is to determine what effect Magnevist (gadopentetate dimeglumine) injection has on the way the heart conducts the electrical impulses that allow it to beat effectively. The study will compare Magnevist injection's effect to that of placebo (a saline injection).

Timeline

Start
2004-01
Primary completion
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.1 mmol
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.3 mmol
Comparator Moxifloxacin Small molecule 400 mg

Indications

No indication recorded.